• Mashup Score: 0
    Quality of Life in the Treatment of mHSPC: The STAMPEDE Trial - Hannah Rush - 4 year(s) ago

    Hannah Rush joins Alicia Morgans discussing the quality of life outcomes we have seen from patients receiving docetaxel or abiraterone in the STAMPEDE trial. STAMPEDE is a multi-arm, multi-stage trial investigating various therapeutic strategies for the management of locally advanced or metastatic hormone-naïve prostate cancer. In recent years, both docetaxel and abiraterone have been shown to…

    Source: UroToday
    Categories: Latest Headlines, Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Quality of life in the treatment of #mHSPC: The #STAMPEDE trial. @HannahR08378281 @ucl joins @CaPsurvivorship @NUFeinbergMed to discuss treatment considerations for newly diagnosed mHSPC patients. #WatchNow on UroToday > https://t.co/8BVx8nanXS @MRCCTU @ASCO #GU20 https://t.co/mOQB8WS0WY

  • Mashup Score: 0
    Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer from a Prospective Randomized Trial - Felix Feng - 4 year(s) ago

    Alicia Morgans is joined by Felix Feng to discuss his recent presentation on a new analysis from the Phase III RTOG 9601 trial. They discuss the application of using Decipher, a test based on gene expression profiles in primary tumors in prostate cancer, which adds significantly to identifying the men with the most aggressive disease. It drives the discussion to when we adopt genomic biomarkers…

    Source: UroToday
    Categories: Latest Headlines, Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Validation of a prognostic genomic classifier in salvage radiotherapy #ProstateCancer from a prospective randomized trial. @felixfengmd @UCSF joins @CaPsurvivorship @NUFeinbergMed to discuss a new analysis from RTOG 9601 > https://t.co/DnKSCvkgq3 @ASCO #GU20 @decipher_bio https://t.co/ehrQrw3dLW

  • Mashup Score: 0
    Making Quality Inferences from GU ASCO Quality of Life Data: How I Interpret the Evidence - 4 year(s) ago

    measuring quality of life data for patients with prostate cancer, quality of life during treatment with chemotherapy, quality of life data from the CARD trial, quality of life data from the STAMPEDE trial, GU ASCO 2020 quality of life CARD data

    Source: www.urotoday.com
    Categories: Latest Headlines, Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Making quality inferences from @ASCO #GU20 Quality of Life data: How I interpret the evidence. New #blog by @CaPsurvivorship @NUFeinbergMed providing a detailed understanding of the data from #STAMPEDE & #CARD and how it can be used. #ReadNow on UroToday > https://t.co/X0KryPzjBi https://t.co/1WZstLKNL3

  • Mashup Score: 0
    Association of metagene based on gene expression with response to atezolizumab (atezo) for metastatic urothelial carcinoma (mUC). - 4 year(s) ago

    569 Background: Despite the benefits of PD1/L1 inhibitors in metastatic urothelial carcinoma (mUC), the durable benefits accrue mostly to a minority of patients (pts) who attain ≥partial response (PR) by RECIST 1.1. There is a pressing need to identify pts with a low probability of response, who may be diverted to other regimens or trials. Biomarkers associated with response such as PD-L1…

    Source: Journal of Clinical Oncology
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of sonpavde
      sonpavde

      #bladdercancer #research monthly web meeting @danafarber well attended- talk by @aravi1 @broadinstitute -leveraging gene expression to develop #precisionmedicine-follows recent #GU20 presentation-vital to make progress in #cancer #research despite #COVID19 https://t.co/IKKzR7Ou2f https://t.co/1HaA038zjf

  • Mashup Score: 0
    Pembrolizumab in the BCG-unresponsive NMIBC Patients - Arjun Balar - 4 year(s) ago

    Joining Ashish Kamat is Arjun Balar, both experts in the field of bladder cancer and each closely involved with the FDA approval of pembrolizumab in the BCG-unresponsive bladder cancer population. Dr. Balar outlines the history of the drug, how the study which led to the FDA approval in NMIBC was designed. Dr. Balar also expands in his approach to counseling his patients who are considering…

    Source: UroToday
    Categories: Latest Headlines, Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Pembrolizumab in BCG-unresponsive #NMIBC Patients. @ArjunBalarMD @nyulangone joins @UroDocAsh @MDAndersonNews in discussion at @ASCO #GU20. #WatchNow on UroToday > https://t.co/mlVnqJRtDL #BladderCancer https://t.co/tMcMTxUrWz

  • Mashup Score: 0
    Financial Toxicity and Quality of Life: Understanding and Improving Patient-Centered Outcomes in Genitourinary Malignancies - David Penson - 4 year(s) ago

    David Penson provides insights on his keynote lecture from ASCO GU 2020 in this conversation with Alicia Morgans. He focuses on recognizing that methods of effectively measuring a patient’s quality of life are not easy to define. In addition to the physical, psychological and social experiences that contribute to a patient’s quality of life, Dr. Penson argues the growing burden of financial…

    Source: UroToday
    Categories: Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Financial toxicity and quality of life: Understanding and improving patient-centered outcomes in genitourinary malignancies. @urogeek @VUMChealth speaks with @CaPsurvivorship @NUFeinbergMed regarding his keynote lecture @ASCO #GU20. #WatchNow on UroToday > https://t.co/BShqvseiLH https://t.co/GVJj6wmKSs

Load More